Observed cytokine regulation during fedratinib treatment, including downregulation of pro-inflammatory TNF-α, may contribute to improvements in MF symptoms, and upregulation of anti-inflammatory and anti-fibrotic adiponectin may affect bone marrow fibrosis [55]. This evidence concerns the gene TNF and primary myelofibrosis.